Vericel Corporation
Financials
Valuation Metrics
Vericel Corporation's Market Cap is $2.07B. At end of 2025 it was $1.82B. Ranked #1922 of 3,116 in US market (top 62%), #713 of 1,472 on NASDAQ (top 48%), #128 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 48%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.07B | US#1,922/3,116 Sec#128/265 |
| Revenue | $306M | US#2,423/3,116 Sec#96/265 |
| Net Income | $24M | US#2,059/3,116 Sec#66/265 |
| Total Assets | $503M | US#2,754/3,116 Sec#164/265 |
| Net Assets | $370M | US#2,411/3,116 Sec#141/265 |
| Employees | 398 | US#2,328/3,116 Sec#94/265 |
| Value | ||
| P/E | 85.41x | US#2,064/3,116 Sec#61/265 |
| P/B | 5.59x | US#2,331/3,116 Sec#157/265 |
| PEG | 0.35x | US#484/3,116 Sec#16/265 |
| P/S | 6.75x | US#2,535/3,116 Sec#98/265 |
| EV/EBITDA | 52.95x | US#2,364/3,116 Sec#73/265 |
| FCF Yield | 2.40% | US#1,973/3,116 Sec#66/265 |
| Profitability | ||
| ROE | 6.55% | US#1,716/3,116 Sec#55/265 |
| ROA | 4.82% | US#1,080/3,116 Sec#52/265 |
| Op. Margin | 5.95% | US#1,878/3,116 Sec#70/265 |
| Revenue Growth | 22.95% | US#588/3,116 Sec#70/265 |
| Earnings Growth | 240.80% | US#134/3,116 Sec#7/265 |
| Financial Health | ||
| Debt Ratio | 35.89% | US#405/3,116 Sec#117/265 |
| Total Debt | $93M | US#2,450/3,116 Sec#125/265 |
| FCF | $50M | US#1,986/3,116 Sec#71/265 |
| Cash | $125M | US#2,062/3,116 Sec#151/265 |
| Current Ratio | 5.04x | US#464/3,116 Sec#142/265 |
| Net Debt/EBITDA | -0.85x | US#319/3,116 Sec#21/265 |
| Performance | ||
| 1Y Return | 15.54% | US#1,088/3,116 Sec#107/265 |
| 1M Return | 0.90% | US#1,202/3,116 Sec#77/265 |
| From 52W High | -17.86% | US#1,081/3,116 Sec#64/265 |
| 1Y MDD | -31.03% | US#1,385/3,116 Sec#69/265 |
| Trading | ||
| Volume | 510,197 shares | US#2,063/3,116 Sec#202/265 |
| Trading Value | $21M | US#1,867/3,116 Sec#144/265 |
| Per Share | ||
| EPS | $0.47 | US#1,883/3,116 Sec#60/265 |
| BPS | $7.25 | US#2,059/3,116 Sec#95/265 |
Company Info
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.